P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients

Rok, strany: 2006, 43 - 48

Diversity of P53 impact on tumor angiogenesis is due to the fact that wild-type P53 decreases expression of vascular endothelial growth factor (VEGF), but mutant P53 upregulates it. Therefore, we aimed at uncovering relations between preoperative serum levels of VEGF and P53 in colorectal cancer (CRC) patients. Preoperative blood samples of 125 CRC patients and 16 control healthy volunteers were examined with an ELISA-kit for serum P53 levels and VEGF. P53 did not correlate with VEGF in the whole group of CRC patients. However, P53 associated with VEGF in case of colorectal cancer patients, whose serum values of VEGF were higher than in controls (VEGF{H} >5.9333 pg/ml) (r=0.274, p<0.009). We revealed a positive correlation between P53 and VEGF{H} in subsets of poorly differentiated (G3) cancers (p<0.02), lymph node positive (p<0.007), pT3 or pT4 patients (p<0.004) without analogous relation in moderately differentiated (G2) tumors, node negative patients or pT1 or pT2 patients. P53 and IGF-I negatively correlated in all CRC patients (p<0.04) and VEGF{H} individuals of pT3 or pT4 (p<0.05) without any significant linkage in tumors of pT1 or pT2. The positive correlation between serum P53 and VEGF points at mutation of P53 and is a highly probable sign of poor prognosis in colorectal cancer. For now it can not be excluded that the binary analysis of serum P53 and VEGF could help select CRC patients endangered by rapid growth and lymph node metastases.

ISO 690:

Famulski, W., Sulkowska, M., Wincewicz, A., Kedra, B., Pawlak, K., Zalewski, B., Sulkowski, S., Koda, M., Baltaziak, M. 2006. P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. In NEOPLASMA, vol. 53, no.1, pp. 43-48. 0028-2685.

APA:

Famulski, W., Sulkowska, M., Wincewicz, A., Kedra, B., Pawlak, K., Zalewski, B., Sulkowski, S., Koda, M., Baltaziak, M. (2006). P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. NEOPLASMA, 53(1), 43-48. 0028-2685.